Published in Am J Transplant on April 01, 2003
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther (2015) 1.20
Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol (2006) 1.18
Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol (2005) 1.12
CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet (2005) 0.99
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol (2014) 0.92
Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol (2007) 0.91
The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol (2011) 0.90
Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.90
Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant (2011) 0.90
Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS One (2014) 0.90
PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics (2012) 0.87
Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol (2008) 0.86
Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS One (2011) 0.85
Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation (2012) 0.85
Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur J Clin Pharmacol (2011) 0.84
Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation. Curr Opin Immunol (2008) 0.81
Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr Nephrol (2014) 0.81
Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatr Nephrol (2014) 0.80
Design of Allele Specific PCR for Rapid Detection of CYP3A5 (A6986G) and Mdr-1 (C3435T) Polymorphisms. Indian J Clin Biochem (2010) 0.79
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J Clin Pharmacol (2006) 0.78
Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients. Indian J Nephrol (2010) 0.77
Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. Eur J Clin Pharmacol (2005) 0.77
Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatr Nephrol (2012) 0.76
The challenge of renal function in heart transplant children. Pediatr Nephrol (2006) 0.76
Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients. Saudi J Gastroenterol (2013) 0.75
Pharmacogenomics: personalizing pediatric heart transplantation. Circulation (2015) 0.75
A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation. AAPS J (2013) 0.75
The role of genetics in drug dosing. Pediatr Nephrol (2012) 0.75
Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies. World J Pediatr (2017) 0.75
Personalized treatment in heart transplantation. Curr Opin Organ Transplant (2017) 0.75
Mapping the genetic architecture of gene expression in human liver. PLoS Biol (2008) 19.44
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med (2006) 3.16
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet (2011) 2.68
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Hospitalization of nursing home residents: the effects of states' Medicaid payment and bed-hold policies. Health Serv Res (2007) 2.41
The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med (2014) 2.38
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy (2008) 2.34
Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion (2006) 2.26
Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation (2006) 2.24
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res (2010) 2.06
Surgical treatment of 31 complex traumatic posterior urethral strictures associated with urethrorectal fistulas. Eur Urol (2009) 2.05
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther (2003) 1.94
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol (2002) 1.91
Time-dependent, protein-directed growth of gold nanoparticles within a single crystal of lysozyme. Nat Nanotechnol (2011) 1.77
A target-responsive electrochemical aptamer switch (TREAS) for reagentless detection of nanomolar ATP. J Am Chem Soc (2007) 1.69
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant (2003) 1.58
Transperineal bulboprostatic anastomosis in patients with simple traumatic posterior urethral strictures: a retrospective study from a referral urethral center. Urology (2009) 1.55
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics (2011) 1.50
Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48
Transpubic access using pedicle tubularized labial urethroplasty for the treatment of female urethral strictures associated with urethrovaginal fistulas secondary to pelvic fracture. Eur Urol (2008) 1.46
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant (2005) 1.46
Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosis. Nephrology (Carlton) (2012) 1.45
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Percutaneous translumbar spinal cord compression injury in a dog model that uses angioplasty balloons: MR imaging and histopathologic findings. AJNR Am J Neuroradiol (2003) 1.43
Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem (2009) 1.40
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos (2007) 1.40
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
Invasive fungal infections in pediatric heart transplant recipients: incidence, risk factors, and outcomes. Pediatr Transplant (2010) 1.39
Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol (2008) 1.38
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr (2006) 1.35
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant (2007) 1.30
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics (2002) 1.30
Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med (2003) 1.28
HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant (2004) 1.27
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol (2002) 1.26
Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation (2006) 1.24
Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther (2005) 1.23
Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg (2009) 1.21
Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant (2003) 1.21
Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant (2012) 1.18
Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther (2004) 1.18
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res (2008) 1.17
Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum Immunol (2003) 1.17
Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol (2008) 1.16
An enzyme-based E-DNA sensor for sequence-specific detection of femtomolar DNA targets. J Am Chem Soc (2008) 1.15
Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am (2003) 1.14
Correlation of accelerometry with clinical balance tests in older fallers and non-fallers. Age Ageing (2009) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol (2004) 1.12
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood (2003) 1.10
Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant (2005) 1.09
Interleukin-6 promoter -174 polymorphism and spontaneous preterm birth. Am J Obstet Gynecol (2003) 1.08
The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.08
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther (2006) 1.06
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics (2009) 1.05
Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab (2005) 1.04
Best practice in group-based smoking cessation: results of a literature review applying effectiveness, plausibility, and practicality criteria. Am J Health Promot (2004) 1.04
G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol (2006) 1.04
Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation (2008) 1.03
Leukocyte capture and modulation of cell-mediated immunity during human sepsis: an ex vivo study. Crit Care (2013) 1.03
Distribution of exonic splicing enhancer elements in human genes. Genomics (2005) 1.03
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol (2004) 1.02
Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation (2006) 1.02
The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One (2011) 1.02
Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med (2003) 1.02
Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation (2009) 1.01
Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation (2012) 1.01
Anti-HLA alloantibodies in pediatric solid organ transplantation. Pediatr Transplant (2006) 1.00
Both cyclin I and p35 are required for maximal survival benefit of cyclin-dependent kinase 5 in kidney podocytes. Am J Physiol Renal Physiol (2012) 1.00
CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem (2011) 1.00
Deletion of the last five C-terminal amino acid residues of connexin43 leads to lethal ventricular arrhythmias in mice without affecting coupling via gap junction channels. Basic Res Cardiol (2013) 1.00
Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. Am J Transplant (2005) 1.00